The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 14, 2025

Filed:

Mar. 27, 2019
Applicants:

Georg-august-universitaet Goettingen, Stiftung Oeffentlichen Rechts, Universitaetsmedizin, Goettingen, DE;

Board of Regents, the University of Texas System, Austin, TX (US);

Inventors:

Michael Zeisberg, Goettingen, DE;

Elisabeth Zeisberg, Goettingen, DE;

Björn Tampe, Goettingen, DE;

Désiree Tampe, Goettingen, DE;

Gerhard Anton Mueller, Tuebingen, DE;

Raghu Kalluri, Houston, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/35 (2006.01); A61K 31/436 (2006.01); A61K 31/4439 (2006.01); A61K 31/496 (2006.01); A61P 1/16 (2006.01); A61P 9/00 (2006.01); A61P 13/12 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 31/436 (2013.01); A61K 31/35 (2013.01); A61K 31/4439 (2013.01); A61K 31/496 (2013.01); A61P 1/16 (2018.01); A61P 9/00 (2018.01); A61P 13/12 (2018.01); C12N 15/1137 (2013.01); C12N 2310/14 (2013.01); C12N 2310/3233 (2013.01);
Abstract

The present disclosure is directed to novel therapeutic approaches for the prevention, treatment and/or delaying progression of chronic injury, progressive loss of functional parenchymal cells, or fibrosis of an organ. Specifically disclosed are agents for use in increasing homodimer-formation of ARNT in an organ in the prevention, treatment and/or delaying progression of chronic injury, progressive loss of functional parenchymal cells, or fibrosis of said organ, as further defined in the claims. In embodiments, said agent may be (i) an inhibitor of protein phosphatase 2A (PP2A) activity, (ii) an inhibitor of the transcriptional repressor complex FKBP12/YY1, or (iii) an expression construct, which is capable of over-expressing ARNT in said organ, as well as combinations of (i), (ii), and/or (iii).


Find Patent Forward Citations

Loading…